2. GPCR/G Protein MAPK/ERK Pathway
  3. Ras
  4. KRASG12C IN-17

KRASG12C IN-17 is an orally active covalent KRASG12C inhibitor, showing strong inhibitory activity in KRASG12C-mutant cancer cells (NCI-H23 IC50 = 0.7 nM; NCI-H358 IC50 = 0.5 nM). KRASG12C IN-17 covalently and irreversibly binds to KRASG12C with > 96% modification efficiency in both GDP-bound and GMPPNP-bound conformations. KRASG12C IN-17 can be used for studies of KRAS-driven cancers, including colorectal cancer.

For research use only. We do not sell to patients.

KRASG12C IN-17

KRASG12C IN-17 Chemical Structure

CAS No. : 2966924-23-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

KRASG12C IN-17 Related Antibodies

Top Publications Citing Use of Products

View All Ras Isoform Specific Products:

View All Isoforms
K-Ras H-Ras N-Ras Ras

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KRASG12C IN-17 is an orally active covalent KRASG12C inhibitor, showing strong inhibitory activity in KRASG12C-mutant cancer cells (NCI-H23 IC50 = 0.7 nM; NCI-H358 IC50 = 0.5 nM). KRASG12C IN-17 covalently and irreversibly binds to KRASG12C with > 96% modification efficiency in both GDP-bound and GMPPNP-bound conformations. KRASG12C IN-17 can be used for studies of KRAS-driven cancers, including colorectal cancer[1].

IC50 & Target

KRas G12C

 

In Vitro

KRASG12C IN-17 (compound 19) potently inhibits KRASG12C-mutant NCI-H23 and NCI-H358 cells with IC50 values of 0.7 nM and 0.5 nM, respectively , following 72-144 hours of incubation[1].
KRASG12C IN-17 covalently modifies KRASG12C in both GDP- and GMPPNP-bound states with >96% conjugation efficiency within 15 minutes[1].
KRASG12C IN-17 inhibits multiple resistance-associated KRASG12C variants, including R68S, H95Q, Y96C and Q99L, in Ba/F3 cells[1].
KRASG12C IN-17 exhibits antiproliferative activity against selected KRASG12C secondary-mutation cancer cell lines, retaining strong potency particularly against Y96C and Q99L variants[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KRASG12C IN-17 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: NCI-H23 (KRASG12C), NCI-H358 (KRASG12C)
Concentration: 0.7 nM (NCI-H23), 0.5 nM (NCI-H358)
Incubation Time: 72 h
Result: Significantly inhibited proliferation of KRASG12C-mutant NCI-H23 and NCI-H358 cells.
In Vivo

KRASG12C IN-17 (30 mg/kg, oral gavage, QD for 28 days) demonstrates strong in vivo activity, producing 103% tumor growth inhibition in SW837 KRASG12C xenograft models[1].
KRASG12C IN-17 (30 mg/kg, oral gavage, QD for 21 days) significantly reduces tumor volume in Ba/F3 KRASG12C/R68S xenograft models, achieving 65.9% tumor reduction[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SW837 human rectal cancer xenograft (KRASG12C) female NOD SCID mice (6–7 weeks old, 20.5–23.7 g)
Dosage: 30 mg/kg
Administration: Oral gavage (p.o.); once daily (QD); 28 days
Result: Achieved 103% tumor growth inhibition and induced near-complete tumor stasis without significant body-weight loss in SW837 KRASG12C xenograft models.
Animal Model: Ba/F3 KRASG12C/R68S xenograft model female NOD SCID mice (6-8 weeks old, 18.6-23.3 g)
Dosage: 30 mg/kg
Administration: Oral gavage (p.o.); once daily (QD); 21 days
Result: Reduced tumor volume by 65.9% and demonstrated good tolerability in Ba/F3 KRASG12C/R68S xenograft models.
Molecular Weight

650.69

Formula

C37H33F3N6O2
CAS No.
SMILES

N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C=C(F)C(C4=C5C(C#C)=CC=CC5=CC=C4)=C(F)C3=NC(OCC67CCCN6CCC7)=N2)C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KRASG12C IN-17 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KRASG12C IN-172966924-23-0RasKRAS G12Ccovalent inhibitorcolorectal cancerNSCLCresistance mutationR68Sxenograftoral bioavailabilitytumor stasisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KRASG12C IN-17
Cat. No.:
HY-179403
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.